(CercleFinance.com) – DBV Technologies unscrews by 12% after the announcement by the biopharmaceutical company that it is initiating a restructuring plan project, ‘in order to extend its cash horizon pending clarifications from the FDA ‘.
She explained that she had not yet received new information concerning her request for a BLA for Viaskin Peanut, and that she had undertaken a complete review of her activities in order to position herself as best as possible in the event of a delay in the examination calendar. .
Following this review, its board of directors approved the immediate initiation of a plan for a global restructuring plan, which should notably include a significant reduction in staff.
– .
